Trials / Terminated
TerminatedNCT01016327
Study of NMS-1116354 in Solid Tumors
A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMS-1116354 | Oral daily administration for 7 consecutive days every 14 days |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-12-01
- Completion
- 2012-09-01
- First posted
- 2009-11-19
- Last updated
- 2012-09-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01016327. Inclusion in this directory is not an endorsement.